WTX-124 / Werewolf Therap - LARVOL DELTA

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Upcoming Milestones...Dose escalation is ongoing for WTX-124 in combination with pembrolizumab, with updated data and opening of expansion arms anticipated in the second half of 2024; WTX-330: Werewolf anticipates sharing additional results from the checkpoint inhibitor-resistant or -naïve relapsed or refractory advanced tumor patient expansion arms in the fourth quarter of 2024."

P1 data • Hematological Malignancies • Lymphoma • Melanoma • Non-Hodgkin’s Lymphoma • Oncology • Skin Cancer • Solid Tumor

A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab. (ASCO 2024) - P1 | "WTX-124 administered as a monotherapy IV Q2W in the outpatient setting is well tolerated and clinically active in patients with relapsed/refractory solid tumors after checkpoint inhibitor therapy. Preliminary results from the ongoing combination dose escalation with pembrolizumab show no new safety signals. Updated data on safety, biomarkers, and preliminary clinical activity for the combination will be presented."

Checkpoint inhibition • Clinical • IO biomarker • Metastases • P1 data • Esophageal Cancer • Fatigue • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Melanoma • Musculoskeletal Pain • Non-melanoma Skin Cancer • Oncology • Pain • Pruritus • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • IL2 • PD-L1

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors (GlobeNewswire) - P1/1b | N=150 | NCT05479812 | Sponsor: Werewolf Therapeutics, Inc. | "Werewolf Therapeutics, Inc...announced new clinical data from the Phase 1/1b trial evaluating WTX-124...WTX-124 as a monotherapy produced three objective clinical responses including one durable confirmed complete response (CR) and two partial responses (PRs) in patients who are relapsed/refractory to immune checkpoint inhibitor therapy....Based on these results, Werewolf has selected a WTX-124 monotherapy dose of 18 mg administered intravenously every two weeks (IV Q2W), as the RDE to progress into the Phase 1b dose-expansion portion of the trial. The Company has thus far opened three expansion arms in advanced or metastatic renal cell carcinoma, cutaneous melanoma and cutaneous squamous cell carcinoma. Werewolf also continues to dose-escalate WTX-124 in combination with pembrolizumab and expects to select an RDE to open the combination dose-expansion portion of the study in the third quarter of 2024."

P1 data • Trial status • Cutaneous Melanoma • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Skin Cancer • Solid Tumor

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting (GlobeNewswire) - "Werewolf Therapeutics, Inc...announced the upcoming presentation of clinical data from dose-escalation arms of the Phase 1/1b trial evaluating WTX-124, its conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, as monotherapy and in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy. Highlights from the data as of January 28, 2024, were published today in an abstract for the upcoming poster presentation, which will include additional data from a May 1, 2024, cut-off date, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois."

P1 data • Solid Tumor

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) - "At the American Society for Clinical Oncology (ASCO) Annual Meeting, the Company will present additional interim data from the monotherapy dose-escalation arm and preliminary dose-escalation data from the combination arm of its ongoing Phase 1/1b clinical trial of WTX-124....Werewolf remains on track to select a recommended dose for expansion and initiate monotherapy dose expansion arms in the first half of 2024....In the second quarter of 2024, Werewolf plans to present interim first-in-human data from Study WTX-330x2101, its Phase 1, multi-center, open-label clinical trial evaluating WTX-330 as a monotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-Hodgkin lymphoma."

P1 data • Trial status • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) - "Werewolf Therapeutics, Inc...today announced that an abstract providing an update of the Company’s ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 (IL-2) INDUKINE molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois."

P1 data • Solid Tumor

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) - "In the first half of this year, we plan to present additional clinical data from our Phase 1/1b clinical trial of WTX-124, including updated monotherapy data and initial combination data, which we anticipate will build on the promising signals of antitumor activity and improved therapeutic index that we observed in the data presented at SITC last year. In addition, we plan to share data further demonstrating the performance of our platform in our preclinical programs at AACR. We also plan to share initial clinical data from WTX-330, our second clinical candidate, in the second quarter of 2024."

P1 data • Preclinical • Non-Hodgkin’s Lymphoma • Solid Tumor

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook (GlobeNewswire) - "WTX-124: In the first half of 2024, Werewolf plans to: Report updated interim data from the monotherapy dose-escalation arm of the Phase 1/1b study; Select a recommended dose for expansion (RDE) and initiate monotherapy dose expansion arms; and Report initial data from the combination dose escalation cohorts of the Phase 1/1b study."

P1 data • Trial status • Oncology • Solid Tumor

WTX-124: “WTX-124 administered as a monotherapy IV Q2W has been well tolerated and reached exposures associated with intratumoral IL-2 pharmacodynamic activity and clinical responses despite enrollment of a heterogeneous patient population and small patient numbers“; Solid tumors (Werewolf Therapeutics) - Conference Call Presentation

P1 data • Oncology • Solid Tumor

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (Yahoo Finance) - "Research and development expenses: Research and development expenses were $10.8 million for the third quarter of 2023, compared to $13.1 million for the same period in 2022. The decrease in research and development expenses was primarily due to a decrease in contract manufacturing costs associated with WTX-124 and WTX-330. The decline in contract manufacturing costs was partially offset by an increase in clinical trial costs for WTX-124 and WTX-330."

Commercial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules (SITC 2023) - P1 | "The models also show that substantially higher doses of the tumor-activated non-alpha IL-2 molecule are required to attain the same RO on TILs as WTX-124. A first-in-human clinical trial of WTX-124 is presently underway (NCT05479812)."

Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8

Spatial analysis of tumor infiltrating lymphocyte populations in syngeneic mouse tumor models after treatment with IL-12 (mWTX-330) and IL-2 (WTX-124) INDUKINETM molecules (SITC 2023) - "This phenomenon was further amplified by combination treatment with blockers of the PD-1 pathway, highlighting the potential for INDUKINETM treatments to amplify the effects of checkpoint inhibitors. Conclusions Treatment of murine tumor bearing mice with either mWTX-330 or WTX-124 resulted in significant remodeling of immune cell populations found within the tumor tissue, simultaneously increasing immune cell infiltration, and generating a potent activation of effector cells."

IO biomarker • Preclinical • Tumor-infiltrating lymphocyte • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • GZMB • IL12A • IL2

Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINETM molecule that releases fully potent IL-2 in the tumor microenvironment (SITC 2023) - P1 | "This data corroborates recent publications demonstrating that IL-2 non-alpha molecules fail to take full advantage of the positive antitumor biology generated by IL-2. WTX-124 is currently in Phase I clinical testing (NCT05678998)."

Biomarker • Clinical • Tumor microenvironment • Oncology • CD4 • CD8 • FOXP3 • IFNG • IL2

A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors (SITC 2023) - P1 | "PK data show sustained prodrug exposure in plasma with low levels of active IL-2. The data demonstrate the potential of WTX-124 to safely deliver a fully potent, wild-type IL-2 to the TME in patients with solid tumors."

Clinical • Combination therapy • IO biomarker • Metastases • P1 data • Cutaneous Melanoma • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • PD-L1

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - P1 | N=75 | NCT05678998 | Sposnor: Werewolf Therapeutics, Inc. | "Werewolf Therapeutics, Inc...announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124x2101....WTX-124 showed expected pharmacokinetics with evidence of wide therapeutic index allowing for continued dose escalation. WTX-124 demonstrated both translational biomarker activity and early evidence of monotherapy antitumor activity at 6 mg and 12 mg doses. CD8+ T and NK cell proliferation and activation in the tumor microenvironment and immune cell gene expression changes were seen at 6 mg and 12 mg dose levels....Dose escalation is ongoing in the monotherapy and combination therapy arms of the trial with additional data from monotherapy dose-escalation cohorts informing declaration of recommended dose for expansion (RDE) and opening of the monotherapy expansion arms expected in the first half of 2024."

P1 data • PK/PD data • Trial status • Oncology • Solid Tumor

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - "Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting....Tumor growth over time was measured in mice bearing syngeneic tumors treated with either mWTX-330 (a chimeric IL-12 containing INDUKINE molecule) or WTX-124 (a human IL-2 containing INDUKINE molecule) using various techniques, including high-plex immunofluorescence, resulting in significant remodeling of immune cell populations found within the tumor tissue and simultaneously increased immune cell infiltration generating a potent activation of effector cells....Systemic administration of WTX-124 resulted in robust antitumor immunity and preferentially activated tumor-infiltrating immune cells as compared to a non-alpha IL-2 version of the INDUKINE demonstrating that the full activity of IL-2 contained in WTX-124 is required to activate potent antitumor responses."

Preclinical • Oncology

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - P1 | N=150 | NCT05479812 | Sponsor: Werewolf Therapeutics, Inc. | "Werewolf Therapeutics...announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting....As of June 22, 2023, 11 patients with relapsed/refractory solid tumors, including non-small cell lung cancer, cutaneous melanoma and renal cell carcinoma were treated with WTX-124 in three monotherapy dose escalation cohorts of 1, 3 and 6 mg administered intravenously every two weeks. WTX-124 was well-tolerated with no dose limiting toxicities at doses up to 6mg. Pharmacokinetic data as of June 22, 2023, demonstrated WTX-124 sustained prodrug exposure in plasma with low levels of active IL-2."

P1 data • PK/PD data • Cutaneous Melanoma • Non Small Cell Lung Cancer • Renal Cell Carcinoma

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (GlobeNewswire) - "Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meeting; Company to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124."

P1 data • Preclinical • Oncology • Solid Tumor

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124 (GlobeNewswire) - "Werewolf management will also provide an overview of the Company’s PREDATOR™ platform and spotlight the clinical program for its IL-2 targeted INDUKINE™ molecule, WTX-124, followed by a Q&A session."

Clinical • Oncology • Solid Tumor

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) - "Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023."

P1 data • Oncology • Solid Tumor

Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors (AACR 2023) - P1 | "Pre- and on-treatment tumor biopsies, archival tumor tissue, and blood samples will be used to investigate multiple exploratory biomarkers. As of January 12, 2023, WTX-124 monotherapy dose escalation is proceeding."

Clinical • Combination therapy • IO biomarker • Metastases • Monotherapy • P1 data • Cutaneous Melanoma • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) - "WTX-124: Enrollment is ongoing in monotherapy dose-escalation cohorts, and the Company anticipates reporting interim safety, tolerability and preliminary efficacy data from these monotherapy cohorts in the fourth quarter of 2023."

P1 data • Oncology • Solid Tumor

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 (GlobeNewswire) - "Werewolf Therapeutics, Inc...announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida."

Clinical data • Trial status • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023 (GlobeNewswire) - "Werewolf Therapeutics, Inc...announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida."

Clinical data • Oncology • Solid Tumor

Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) - "Werewolf is actively enrolling patients in monotherapy dose-escalation cohorts in Study WTX-124x2101. The Company anticipates reporting preliminary interim data from this study in the fourth quarter of 2023. These data are expected to provide initial safety and activity profiles of WTX-124."

Enrollment status • P1 data • Oncology • Solid Tumor